Oriol Canela-Xandri

Oriol Canela-Xandri

Auto-generated profile, based on publicly available information

Oriol Canela-Xandri

MRC Human Genetics Unit at the Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
OCOriol Canela-Xandri
Oriol Canela-Xandri
KRKonrad Rawlik
Konrad Rawlik
ATAlbert Tenesa
Albert Tenesa

11 August 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SLShuli Liu
Shuli Liu
YGYahui Gao
Yahui Gao
OCOriol Canela-Xandri
Oriol Canela-Xandri
SWSheng Wang
Sheng Wang
YYYing Yu
Ying Yu
LFLingzhao Fang
Lingzhao Fang
Characterization of genetic regulatory variants acting on livestock gene expression is essential for interpreting the molecular mechanisms underlying traits of economic value and for increasing the rate of genetic gain through artificial selection. Here we build a Cattle Genotype–Tissue Expression atlas (CattleGTEx) as part of the pilot phase of the Farm animal GTEx (FarmGTEx) project for the research community based on 7,180 publicly available RNA-sequencing (RNA-seq) samples. We describe the transcriptomic landscape of more than 100 tissues/cell types and report hundreds of thousands of genetic associations with gene expression and alternative splicing for 23 distinct tissues. We evaluate the tissue-sharing patterns of these genetic regulatory effects, and functionally annotate them using multiomics data. Finally, we link gene expression in different tissues to 43 economically important traits using both transcriptome-wide association and colocalization analyses to decipher the molecular regulatory mechanisms underpinning such agronomic traits in cattle.

7 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EBElena Bernabeu
Elena Bernabeu
OCOriol Canela-Xandri
Oriol Canela-Xandri
KRKonrad Rawlik
Konrad Rawlik
ATAndrea Talenti
Andrea Talenti
JPJames Prendergast
James Prendergast
ATAlbert Tenesa
Albert Tenesa

18 July 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MMMaria Munoz
Maria Munoz
RPRicardo Pong-Wong
Ricardo Pong-Wong
OCOriol Canela-Xandri
Oriol Canela-Xandri
KRKonrad Rawlik
Konrad Rawlik
CHChris S Haley
Chris S Haley
ATAlbert Tenesa
Albert Tenesa

6 July 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
ABAndrew D. Bretherick
Andrew D. Bretherick
OCOriol Canela-Xandri
Oriol Canela-Xandri
PJPeter Joshi
Peter Joshi
DCDavid W. Clark
David W. Clark
KRKonrad Rawlik
Konrad Rawlik
CHChris Haley
Chris Haley
To efficiently transform genetic associations into drug targets requires evidence that a particular gene, and its encoded protein, contribute causally to a disease. To achieve this, we employ a three-step proteome-by-phenome Mendelian Randomization (MR) approach. In step one, 154 protein quantitative trait loci (pQTLs) were identified and independently replicated. From these pQTLs, 64 replicated locally-acting variants were used as instrumental variables for proteome-by-phenome MR across 846 traits (step two). When its assumptions are met, proteome-by-phenome MR, is equivalent to simultaneously running many randomized controlled trials. Step 2 yielded 38 proteins that significantly predicted variation in traits and diseases in 509 instances. Step 3 revealed that amongst the 271 instances from GeneAtlas (UK Biobank), 77 showed little evidence of pleiotropy (HEIDI), and 92 evidence of colocalization (eCAVIAR). Results were wide ranging: including, for example, new evidence for a causal role of tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1; SIRPA) in schizophrenia, and a new finding that intestinal fatty acid binding protein (FABP2) abundance contributes to the pathogenesis of cardiovascular disease. We also demonstrated confirmatory evidence for the causal role of four further proteins (FGF5, IL6R, LPL, LTA) in cardiovascular disease risk. The targets of most medications prescribed today are proteins. For many common diseases our understanding of the underlying causes is often incomplete, and our ability to predict whether new drugs will be effective is remarkably poor. Attempts to use genetics to identify drug targets have an important limitation: standard study designs link disease risk to DNA but do not explain how the genotype leads to disease. In our study, we made robust statistical links between DNA variants and blood levels of 249 proteins, in two separate groups of Europeans. We then used this information to predict protein levels in large genetic studies. In many cases, this second step gives us evidence that high or low levels of a given protein play a role in causing a given disease. Among dozens of high-confidence links, we found new evidence for a causal role of a protein called SHPS1 in schizophrenia, and of another protein (FABP2) in heart disease. Our method takes advantage of information from large numbers of existing genetic studies to prioritize specific proteins as drug targets.

9 April 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
YLYabo Li
Yabo Li
HCHyosuk Cho
Hyosuk Cho
FWFan Wang
Fan Wang
OCOriol Canela‐Xandri
Oriol Canela‐Xandri
CLChunyan Luo
Chunyan Luo
QWQing Wang
Qing Wang
Background: Epistasis describes how gene‐gene interactions affect phenotypes, and could have a profound impact on human diseases such as coronary artery disease ( CAD ). The goal of this study was to identify gene‐gene interactions in CAD using an easily generalizable multi‐stage approach. Methods and Results: Our forward genetic approach consists of multiple steps that combine statistical and functional approaches, and analyze information from global gene expression profiling, functional interactions, and genetic interactions to robustly identify gene‐gene interactions. Global gene expression profiling shows that knockdown of ANRIL (DQ485454) at 9p21.3 GWAS (genome‐wide association studies) CAD locus upregulates TMEM 100 and TMEM 106B . Functional studies indicate that the increased monocyte adhesion to endothelial cells and transendothelial migration of monocytes, 2 critical processes in the initiation of CAD , by ANRIL knockdown are reversed by knockdown of TMEM 106B , but not of TMEM 100 . Furthermore, the decreased monocyte adhesion to endothelial cells and transendothelial migration of monocytes induced by ANRIL overexpression was reversed by overexpressing TMEM 106B . TMEM 106B expression was upregulated by >2‐fold in CAD coronary arteries. A significant association was found between variants in TMEM 106B (but not in TMEM 100 ) and CAD ( P =1.9×10 −8 ). Significant gene‐gene interaction was detected between ANRIL variant rs2383207 and TMEM 106B variant rs3807865 ( P =0.009). A similar approach also identifies significant interaction between rs6903956 in ADTRP and rs17465637 in MIA 3 ( P =0.005). Conclusions: We demonstrate 2 pairs of epistatic interactions between GWAS loci for CAD and offer important insights into the genetic architecture and molecular mechanisms for the pathogenesis of CAD . Our strategy has broad applicability to the identification of epistasis in other human diseases.